NIH AIDS Reagent Program
20301 Century Boulevard
Building 6, Suite 200
Germantown, MD 20874
USA

Phone: 240 686 4740
Fax: 301 515 4015
aidsreagent.org

DATA SHEET

Reagent:	Human APOBEC3G Myc His Expression Vector (pHIV-APO3G)
Catalog Number:	9905
Lot Number:	032581
Release Category:	C
Provided:	1 µg of plasmid DNA in water (0.1 µg/µL)
Cloning Site:	APOBEC3G gene was cloned into the *Bss*HII/*Xho*I sites of pNL4-3 (Cat# 114). The size of the insert is 1240 bp.
Cloning Vector:	The cloning vector is pNL4-3; the size of the cloning vector including the insert is 7941 bp.
Description:	This plasmid expresses human APOBEC3G under the control of the HIV-1 promoter. Requires Tat for expression. APOBEC3G was cloned by PCR from pcDNA-APO3G (Cat# 9904). Expresses a 409 amino acid protein (384 residues APOBEC3G plus 25 residues MycHis epitope tag). Note: this clone contains two nucleotide changes (G1448→A) & (G2071→T) in APOBEC3G resulting in two amino acid changes (S162N) & (D370Y) relative to the GenBank entries for APOBEC3G (NM_021822) and MDS019 (AF182420). Also, note that this plasmid has an extra third band when digested but this does not affect the expression of the APOBEC3G protein in a Tat dependent manner.
Special Characteristics:	Expresses biologically active human APOBEC3G under the control of the HIV-1 LTR. Protein expression is Tat-dependent. Vector restricts APOBEC3G expression to HIV-expressing cells.
Recommended Storage:	-70°C
Contributor:	Drs. Klaus Strebel and Sandra Kao.

References:

Kao S, Khan MA, Miyagi E, Plishka R, Buckler-White A, Strebel K. The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity. *J Virol* **77**:11398-11407, 2003.

NOTE:

Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: pHIV-APO3G from Drs. Klaus Strebel and Sandra Kao." Also include the reference cited above in any publications.

Scientists at for-profit institutions or who intend commercial use of this reagent must contact the NIH Office of Technology Transfer,
Email: NIAIDAIDSReagent@niaid.nih.gov, before the reagent can be released.
Please specify the name and a description of the intended use of the reagent.

Last Updated: July 12, 2017